AR098950A1 - Anticuerpo contra bdca-2 humano - Google Patents
Anticuerpo contra bdca-2 humanoInfo
- Publication number
- AR098950A1 AR098950A1 ARP140104899A ARP140104899A AR098950A1 AR 098950 A1 AR098950 A1 AR 098950A1 AR P140104899 A ARP140104899 A AR P140104899A AR P140104899 A ARP140104899 A AR P140104899A AR 098950 A1 AR098950 A1 AR 098950A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- seq
- acid sequence
- region consisting
- bdca
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporciona un anticuerpo contra Antígeno 2 de las células dendríticas de sangre (BDCA-2) humano para prevenir o tratar una enfermedad autoinmune mediante la unión a un BDCA-2 humano para controlar la función de una célula dendrítica plasmocitoide a través de BDCA-2 humano. Se han investigado anticuerpos contra BDCA-2 humano, y como resultado, han proporcionado un anticuerpo contra BDCA-2 humano que comprende una región variable de cadena pesada que consiste en la secuencia de aminoácidos de los números de aminoácidos 1 a 120 de SEC ID Nº 2 y una región variable de cadena ligera que consiste en la secuencia de aminoácidos de los números de aminoácidos 1 a 109 de SEC ID Nº 4, una región variable de cadena pesada que consiste en la secuencia de aminoácidos de los números de aminoácidos 1 a 120 de SEC ID Nº 6 y una región variable de cadena ligera que consiste en la secuencia de aminoácidos de los números de aminoácidos 1 a 108 de SEC ID Nº 8, y una región variable de cadena pesada que consiste en la secuencia de aminoácidos de los números de aminoácidos 1 a 122 de SEC ID Nº 10 y una región variable de cadena ligera que consiste en la secuencia de aminoácidos de los números de aminoácidos 1 a 108 de SEC ID Nº 12.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013265304 | 2013-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098950A1 true AR098950A1 (es) | 2016-06-22 |
Family
ID=53478667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104899A AR098950A1 (es) | 2013-12-24 | 2014-12-23 | Anticuerpo contra bdca-2 humano |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10294301B2 (es) |
| EP (1) | EP3088519A4 (es) |
| JP (1) | JP6604204B2 (es) |
| KR (1) | KR20160099083A (es) |
| CN (3) | CN114292331A (es) |
| AR (1) | AR098950A1 (es) |
| BR (1) | BR112016014920A2 (es) |
| CA (1) | CA2934604A1 (es) |
| MX (1) | MX2016008520A (es) |
| RU (1) | RU2016129744A (es) |
| TW (1) | TW201609806A (es) |
| WO (1) | WO2015098813A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3034420A1 (fr) * | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-cd303 |
| WO2018185284A1 (en) * | 2017-04-07 | 2018-10-11 | Miltenyi Biotec Gmbh | POLYPEPTIDES WITH MUTANT HUMAN IgG4 |
| PE20201343A1 (es) | 2018-04-02 | 2020-11-25 | Bristol Myers Squibb Co | Anticuerpos anti-trem-1 y usos de los mismos |
| CA3147096A1 (en) * | 2019-08-05 | 2021-02-11 | Steve Holmes | Anti bdca-2 antibodies |
| CA3203971A1 (en) * | 2020-12-03 | 2022-06-09 | Biogen Ma Inc. | Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus |
| CN113549152B (zh) * | 2021-07-22 | 2023-06-20 | 中国人民解放军空军军医大学 | 一种抗basigin人源化抗体及其应用 |
| WO2024010118A1 (ko) * | 2022-07-07 | 2024-01-11 | 주식회사 유틸렉스 | 항 bdca-2 항체 및 이의 용도 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DK0690132T3 (da) | 1993-03-11 | 2004-04-13 | Chemo Sero Therapeut Res Inst | Monoklonalt anti-HIV-antistof |
| JP5007007B2 (ja) * | 1999-11-15 | 2012-08-22 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2002090510A2 (en) * | 2001-05-08 | 2002-11-14 | Emory University | Regulating immine responses using dendritic cells |
| GB0118155D0 (en) * | 2001-07-25 | 2001-09-19 | Lorantis Ltd | Superantigen |
| CN1826356B (zh) * | 2003-07-22 | 2012-05-09 | 克鲁塞尔荷兰公司 | 针对sars冠状病毒的结合分子及其应用 |
| JPWO2006013923A1 (ja) * | 2004-08-05 | 2008-05-01 | Ｓｂｉバイオテック株式会社 | 自己免疫疾患を伴う関節炎の治療剤 |
| AU2005291741B2 (en) * | 2004-10-07 | 2011-11-24 | Universitat Zurich | Type I interferon blocking agents for prevention and treatment of psoriasis |
| SG10201602095PA (en) * | 2005-12-20 | 2016-05-30 | Sbi Biotech Co Ltd | Anti-Ilt7 Antibody |
| EP2083017A4 (en) * | 2006-09-14 | 2011-01-12 | Med & Biological Lab Co Ltd | ANTIBODIES HAVING INCREASED ADCC ACTIVITY AND METHOD FOR PRODUCING THE SAME |
| TWI422594B (zh) * | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| FR2968561B1 (fr) | 2010-12-13 | 2013-08-09 | Lfb Biotechnologies | Utilisation d'un anticorps dirige contre une proteine membranaire |
| TR201819828T4 (tr) * | 2012-01-31 | 2019-01-21 | Sbi Biotech Co Ltd | Anti-fosfolipaz d4 antikoru. |
| EP2928923B1 (en) * | 2012-12-10 | 2020-01-22 | Biogen MA Inc. | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
| AU2014365838B2 (en) | 2013-12-16 | 2021-01-14 | The University Of North Carolina At Chapel Hill | Depletion of plasmacytoid dendritic cells |
| WO2018144955A1 (en) * | 2017-02-02 | 2018-08-09 | Silverback Therapeutics, Inc. | Construct-peptide compositions and methods of use thereof |
-
2014
- 2014-12-22 RU RU2016129744A patent/RU2016129744A/ru not_active Application Discontinuation
- 2014-12-22 CA CA2934604A patent/CA2934604A1/en not_active Abandoned
- 2014-12-22 KR KR1020167012536A patent/KR20160099083A/ko not_active Application Discontinuation
- 2014-12-22 WO PCT/JP2014/083862 patent/WO2015098813A1/ja active Application Filing
- 2014-12-22 CN CN202210015886.1A patent/CN114292331A/zh active Pending
- 2014-12-22 CN CN201811376078.8A patent/CN109535254B/zh active Active
- 2014-12-22 BR BR112016014920A patent/BR112016014920A2/pt not_active Application Discontinuation
- 2014-12-22 EP EP14873919.6A patent/EP3088519A4/en active Pending
- 2014-12-22 CN CN201480070179.6A patent/CN105829534B/zh active Active
- 2014-12-22 JP JP2015554867A patent/JP6604204B2/ja active Active
- 2014-12-22 MX MX2016008520A patent/MX2016008520A/es unknown
- 2014-12-22 US US15/107,660 patent/US10294301B2/en active Active
- 2014-12-23 AR ARP140104899A patent/AR098950A1/es unknown
- 2014-12-23 TW TW103145005A patent/TW201609806A/zh unknown
-
2019
- 2019-04-15 US US16/384,811 patent/US11046770B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11046770B2 (en) | 2021-06-29 |
| US10294301B2 (en) | 2019-05-21 |
| KR20160099083A (ko) | 2016-08-19 |
| CN114292331A (zh) | 2022-04-08 |
| CA2934604A1 (en) | 2015-07-02 |
| MX2016008520A (es) | 2016-11-30 |
| JP6604204B2 (ja) | 2019-11-13 |
| WO2015098813A1 (ja) | 2015-07-02 |
| EP3088519A1 (en) | 2016-11-02 |
| JPWO2015098813A1 (ja) | 2017-03-23 |
| CN105829534B (zh) | 2021-08-03 |
| CN109535254A (zh) | 2019-03-29 |
| EP3088519A4 (en) | 2017-09-13 |
| CN109535254B (zh) | 2022-06-24 |
| BR112016014920A2 (pt) | 2017-12-12 |
| US20190248904A1 (en) | 2019-08-15 |
| US20160319025A1 (en) | 2016-11-03 |
| CN105829534A (zh) | 2016-08-03 |
| RU2016129744A (ru) | 2018-01-30 |
| TW201609806A (zh) | 2016-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098950A1 (es) | Anticuerpo contra bdca-2 humano | |
| AR122771A2 (es) | Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped | |
| CO2020008972A2 (es) | Nanopartícula de lípido que contiene ácido nucleico y uso de la misma | |
| CY1125057T1 (el) | Anti-cd277 αντισωματα και χρησεις αυτων | |
| CY1119283T1 (el) | Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (mhc) ii | |
| CU20170023A7 (es) | Anticuerpos y receptores de antígeno quiméricos específicos para cd19 | |
| CL2016003324A1 (es) | Construcciones de anticuerpos multiespecificos. | |
| EA202090931A3 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
| BR112018068678A2 (pt) | anticorpos anti-mica | |
| BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
| AR090585A1 (es) | Anticuerpos anti-hla-b*27 y usos de estos | |
| ES2672895T3 (es) | Generación de células T específicas de antígeno | |
| PE20141028A1 (es) | Nuevos moduladores y metodos para su uso | |
| CO6351802A2 (es) | Anticuerpos para ccr2 | |
| UY32971A (es) | Proteínas de unión al antígeno de la il-23 humana | |
| BRPI0919473A2 (pt) | Agentes de ligação frizzled e usos dos mesmos | |
| EA201591467A1 (ru) | Анти-lag-3 связывающие белки | |
| CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
| PE20150643A1 (es) | Anticuerpos de reaccion cruzada anti-jagged 1/jagged 2 anticuerpos anti-jagged activables y metodos de uso de los mismos | |
| JP2014005231A5 (es) | ||
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| PE20141166A1 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| BR112019008675A2 (pt) | roedor, célula isolada de roedor, e, métodos de produção de um roedor e de um anticorpo em um roedor. | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| CR20120404A (es) | Proteinas de enlace cd127 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |